U.S. pharma large copyright scrapped two experimental weight loss products past calendar year—a when-each day capsule, lotiglipron, resulting from elevated liver enzymes in addition to a 2 times-day by day pill, danuglipron, due to strong side effects—but CEO Albert Bourla has said the company is set to “Perform and get” from the obesity Ar